U.S Contraceptive Market Size, Share, Growth Analysis, By Type (Drug, Devices), By Age Group (13-19 Years, 20-29 Years) - Industry Forecast 2025-2032

U.S Contraceptive Market size was valued at USD 8.59 billion in 2023 and is poised to grow from USD 8.99 billion in 2024 to USD 12.99 billion by 2032, growing at a CAGR of 4.7% during the forecast period (2025-2032).

The contraception market in the United States is witnessing robust growth, fueled by a surge in modern contraceptive usage and heightened awareness among teens and young adults about sexual health and family planning. Various forms of contraception-both reversible and irreversible-are increasingly accessible, partly due to government initiatives aimed at preventing unplanned pregnancies among youth. According to the Guttmacher Institute, 60% of reproductive-age women currently use contraception, with a notable rise in hormonal methods beyond the traditional birth control pill among married women. This expanded access has positively impacted women's education, career opportunities, and overall economic status, significantly reducing poverty levels associated with unintended pregnancies and childcare costs. Legalized family planning in numerous states has further lessened future economic burdens by improving living standards.

Top-down and bottom-up approaches were used to estimate and validate the size of the U.S Contraceptive market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

U.S Contraceptive Market Segmental Analysis

U.S Contraceptive Market is segmented by Type, and Age Group. Based on Type, the market is segmented into Drug and Devices. Based on Age Group, the market is segmented into 13-19 Years, 20-29 Years, 30-39 Years and 40+ Years.

Driver of the U.S Contraceptive Market

The U.S. contraceptive market is poised for growth, driven in part by the introduction of more effective male contraceptive options. While female contraceptives have dominated the market so far, there is anticipated increased demand for male contraceptives, particularly as the use of male condoms rises. This uptick in condom usage can be attributed to their effectiveness not only in preventing unwanted pregnancies but also in reducing the risk of sexually transmitted diseases (STDs). Additionally, male condoms are favored for their minimal side effects, making them an attractive option for many users, further propelling the market forward.

Restraints in the U.S Contraceptive Market

The U.S. contraceptive market faces several restraints that may hinder its growth. Birth control methods, especially progestin-only pills, can lead to side effects such as irregular bleeding, breast tenderness, nausea, and headaches. Serious complications, albeit rare, include blood clots, heart attacks, strokes, liver disorders, and gallbladder issues. These potential risks will likely impact sales during the forecast period. Additionally, misinformation surrounding contraceptive safety, societal disapproval, and heightened anxiety regarding side effects contribute to hesitancy in adoption. While intrauterine devices (IUDs) are effective, they carry a risk of infection for certain individuals. Though barrier contraception is less efficient, it offers protection against sexually transmitted infections, complicating the decision-making process further.

Market Trends of the U.S Contraceptive Market

The U.S. contraceptive market is trending towards innovation, with a notable rise in the availability of novel oral contraceptives featuring advanced progestins that enhance efficacy and reduce side effects. Despite significant advances, nearly half of all pregnancies remain unintended, underscoring the need for effective contraceptive education and access. The popularity of extended-cycle combination oral contraceptives (COCs), including drospirenone products and chewable pills, reflects changing consumer preferences for convenience and effectiveness. Additionally, while sterilization remains prevalent, many younger women later express regret due to lack of awareness of reversible alternatives. This dual dynamic of innovation and education highlights a critical growth area in the contraceptive landscape.